1. Home
  2. DNUT vs ALLO Comparison

DNUT vs ALLO Comparison

Compare DNUT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.67

Market Cap

585.5M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.32

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
ALLO
Founded
1937
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
585.5M
539.4M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
DNUT
ALLO
Price
$3.67
$2.32
Analyst Decision
Hold
Strong Buy
Analyst Count
5
15
Target Price
$4.15
$8.35
AVG Volume (30 Days)
1.9M
14.4M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
$1,522,616,000.00
N/A
Revenue This Year
$0.55
N/A
Revenue Next Year
$3.59
$142,416.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.58
$0.86
52 Week High
$5.73
$4.46

Technical Indicators

Market Signals
Indicator
DNUT
ALLO
Relative Strength Index (RSI) 50.19 50.05
Support Level $3.09 $2.14
Resistance Level $3.87 $2.71
Average True Range (ATR) 0.24 0.15
MACD -0.02 -0.01
Stochastic Oscillator 13.61 50.00

Price Performance

Historical Comparison
DNUT
ALLO

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: